Higher Revenue and Narrower Operating Loss in Other Businesses
First written in FY2018-Q3. 8 of 22 entries say "Worsened", first in FY2021-Q1. Latest entry: FY2026.
Seed moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2026: 3 of 11 companies on the "Worse" side.
4 other companies' latest entry also says "Other".
- FY2026Lower intraocular lens revenue; Other turns profitableAnnual report
「In Other, revenue was ¥92 million following a decline in intraocular lens revenue, down 26.7% year on year. However, improved margins resulted in operating profit of ¥11 million, compared with an operating loss of ¥8 million in the previous fiscal year.」
Although lower intraocular lens revenue resulted in lower revenue, improved margins shifted Other from an operating loss to operating profit of ¥11 million. - FY2025Higher intraocular lens revenue and a slight narrowing of the operating lossAnnual report
「In Other, higher intraocular lens revenue lifted revenue to ¥126 million, up 9.4% year on year, while the operating loss was ¥8 million, compared with an operating loss of ¥9 million in the previous fiscal year.」
Higher intraocular lens revenue drove a 9.4% year-on-year increase in revenue in Other, while the operating loss narrowed slightly from ¥9 million to ¥8 million. - FY2024-Q3WorsenedAnnual report
「In Other, revenue was ¥87 million following a decline in intraocular lens revenue, down 4.0% year on year, and the operating loss was ¥6 million, compared with an operating loss of ¥5 million in the same period of the previous year.」
The Other segment, which includes intraocular lenses, posted a 4.0% year-on-year decline in revenue, while the operating loss widened from ¥5 million in the same period of the previous year to ¥6 million. - FY2024-Q2WorsenedAnnual report
「In Other, revenue was ¥62 million following a decline in intraocular lens revenue, down 0.6% year on year, and the operating loss was ¥4 million, compared with an operating loss of ¥1 million in the same period of the previous year.」
Lower intraocular lens revenue resulted in a 0.6% year-on-year decline in revenue in Other, while the operating loss widened from ¥1 million to ¥4 million. - FY2023Other reaches operating breakeven after the withdrawalAnnual report
「In Other, following the withdrawal from the eyeglasses wholesale business, revenue was ¥120 million, down 48.2% year on year, and operating income was ¥0 million, compared with an operating loss of ¥98 million in the previous year. This reflected the Company's concentration on the contact lens business.」
After the withdrawal from the eyeglass business, Other posted lower revenue, but operating results improved from an operating loss in the previous year to breakeven. - FY2023-Q2Revenue down, operating loss reducedAnnual report
「In Other, following the withdrawal from the wholesale eyeglass business, revenue was ¥63 million, down 53.1% year on year, and the operating loss was ¥1 million, compared with an operating loss of ¥58 million in the same period of the previous year.」
Following the withdrawal from the wholesale eyeglass business, revenue in Other declined 53.1% year on year, while the operating loss narrowed from ¥58 million to ¥1 million. - FY2023-Q1Lower revenue and a narrower operating loss in Other after exiting the eyeglass businessAnnual report
「In Other, following the withdrawal from the wholesale eyeglass business, revenue was ¥31 million, down 55.6% year on year, and the operating loss was ¥5 million, compared with an operating loss of ¥27 million in the same period of the previous year.」
After the withdrawal from the wholesale eyeglass business, Other posted lower revenue, while the operating loss narrowed from ¥27 million in the same period of the previous year to ¥5 million. - FY2022WorsenedAnnual report
「In Other, revenue was ¥87 million following a decline in intraocular lens revenue, compared with ¥137 million in the same period of the previous year, and the operating loss was ¥10 million, compared with an operating loss of ¥13 million in the same period of the previous year.」
Other posted lower revenue due to a decline in intraocular lens revenue, while the operating loss narrowed slightly from ¥13 million to ¥10 million. - FY2022-Q3WorsenedAnnual report
「In Other, revenue was ¥62 million following a decline in intraocular lens revenue, compared with ¥107 million in the same period of the previous year, and the operating loss was ¥10 million, compared with an operating loss of ¥7 million in the same period of the previous year.」
Lower intraocular lens revenue resulted in lower year-on-year revenue in Other, while the operating loss widened from ¥7 million to ¥10 million. - FY2022-Q2WorsenedAnnual report
「In Other, revenue was ¥44 million following a decline in intraocular lens revenue, compared with ¥78 million in the same period of the previous year, and the operating loss was ¥7 million, compared with an operating loss of ¥6 million in the same period of the previous year.」
In Other, lower intraocular lens revenue reduced revenue from ¥78 million to ¥44 million, while the operating loss widened from ¥6 million to ¥7 million. - FY2021-Q3WorsenedAnnual report
「During the period, a considerable number of ophthalmic facilities restricted surgical procedures to prevent COVID-19 infections. As a result, intraocular lens revenue declined, and revenue in Other was ¥107 million, down 27.4% year on year, while the operating loss was ¥7 million, compared with operating profit of ¥0.5 million in the same period of the previous year.」
The impact of ophthalmic facilities restricting surgical procedures reduced intraocular lens revenue, resulting in a 27.4% year-on-year decline in revenue in Other and a shift from operating profit to an operating loss. - FY2021-Q2WorsenedAnnual report
「In Other, revenue from intraocular lenses declined due to the impact of ophthalmic facilities restricting surgical procedures to prevent the spread of the infection and other factors. Revenue was ¥78 million, down 22.0% year on year, and the operating loss was ¥6 million, compared with operating profit of ¥0.6 million in the same period of the previous year.」
The impact of ophthalmic facilities restricting surgical procedures to prevent the spread of infection reduced intraocular lens revenue, resulting in lower revenue in Other and a shift to an operating loss. - FY2021-Q1WorsenedAnnual report
「In Other, revenue from intraocular lenses declined as some ophthalmic facilities cancelled cataract surgeries due to the impact of COVID-19. As a result, revenue was ¥36 million, down 46.2% year on year, and the operating loss was ¥1 million, compared with operating profit of ¥9 million in the same period of the previous year.」
The cancellation of cataract surgeries at ophthalmic facilities resulted in lower revenue in Other and a shift from operating profit to an operating loss. - FY2020Higher revenue but narrower operating lossAnnual report
「In Other, revenue was ¥309 million, up 38.8% year on year, and the operating loss was ¥11 million, compared with an operating loss of ¥34 million in the same period of the previous year.」
Other posted higher revenue for the full fiscal year, while the operating loss narrowed from ¥34 million to ¥11 million. - FY2020-Q3Continued lower revenue and profitability in OtherAnnual report
「In Other, revenue was ¥147 million, down 13.8% year on year, and operating profit was ¥0.5 million, compared with an operating loss of ¥21 million in the same period of the previous year.」
Although Other posted lower revenue following the segment change, it improved from an operating loss of ¥21 million in the same period of the previous year to operating profit of ¥0.5 million. - FY2020-Q2Lower revenue and a return to profitability in OtherAnnual report
「In Other, revenue was ¥100 million, down 7.6% year on year, and operating profit was ¥0.6 million, compared with an operating loss of ¥16 million in the same period of the previous year.」
Although Other posted lower revenue following the segment change, it improved from an operating loss of ¥16 million to operating profit of ¥0.6 million. - FY2020-Q1ReframedAnnual report
「From the first quarter of the current fiscal year, the segment covering the businesses related to orthokeratology lenses and Triggerfish was changed from Other to Contact Lenses and Care Products based on materiality. Comparisons and analysis for the cumulative first-quarter period are based on the revised segment classification.」
The businesses related to orthokeratology and Triggerfish were moved from Other to Contact Lenses and Care Products, and the segment classification was changed. - FY2019Higher revenue; swing to an operating lossAnnual report
「In Other, the promotion and expansion of orthokeratology lenses, which correct the cornea during sleep when worn before bedtime, and the commencement of deliveries to university hospitals and other institutions of the sensor-equipped so-called medical smart contact lens “Triggerfish” and “Triggerfish Sensor,” whose sales began in December 2018, lifted revenue to ¥431 million, up 27.3% year on year. Regarding profit, increased costs for new introductions of orthokeratology lenses in Hong Kong, Malaysia and other Asian countries and other factors resulted in an operating loss of ¥61 million, compared with operating profit of ¥5 million in the previous fiscal year.」
Revenue increased following the commencement of deliveries of orthokeratology lenses and medical smart contact lenses, while higher costs for new introductions resulted in a shift from operating profit to an operating loss. - FY2019-Q3AdvancedAnnual report
「In Other, the promotion and expansion of orthokeratology lenses, which correct the cornea during sleep when worn before bedtime, lifted revenue to ¥323 million, up 30.0% year on year. However, increased costs for new introductions to overseas business partners and other factors resulted in an operating loss of ¥10 million, compared with an operating loss of ¥31 million in the same period of the previous year.」
The Other segment posted a 30.0% year-on-year increase in revenue due to the promotion and expansion of orthokeratology lenses, while the operating loss narrowed from ¥31 million to ¥10 million. - FY2019-Q2AdvancedAnnual report
「In Other, the promotion and expansion of orthokeratology lenses, which correct the cornea during sleep when worn before bedtime, lifted revenue to ¥204 million, up 23.2% year on year. However, the segment posted an operating loss of ¥1 million, compared with an operating loss of ¥19 million in the same period of the previous year.」
The promotion and expansion of orthokeratology lenses drove a 23.2% year-on-year increase in revenue in Other, while the operating loss narrowed from ¥19 million to ¥1 million. - FY2019-Q1AdvancedAnnual report
「In Other, revenue was ¥93 million, up 24.1% year on year, and operating profit was ¥0.3 million, compared with an operating loss of ¥6 million in the same period of the previous year.」
The Other segment posted a 24.1% year-on-year increase in revenue and improved from an operating loss of ¥6 million to operating profit of ¥0.3 million. - FY2018-Q3First statedAnnual report
「In Other, revenue was ¥248 million, up 29.5% year on year, and the operating loss was ¥31 million, compared with an operating loss of ¥48 million in the same period of the previous year.」
In the Other segment, which includes intraocular lenses and the mobile phone business, revenue increased 29.5% year on year and the operating loss narrowed from ¥48 million to ¥31 million. This was recorded as a separate theme for the first time.